Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1245-1251

  de Melo Campos, Paula ^a   Machado Neto, João A ^a   Scopim Ribeiro, Renata ^a   Visconte, Valeria ^b   Tabarroki, Ali ^b   Duarte, Adriana S S ^a   Barra, Flávia F C ^a   Vassalo, José ^a   Rogers, Heesun J ^c   Lorand Metze, Irene ^a   Tiu, Ramon V ^b   Costa, Fernando F ^a   Olalla Saad, Sara T ^a   Traina, Fabiola ^a,d  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dasatinib; Familial mastocytosis; Imatinib; K509I KIT mutation; PKC412; Tyrosine kinase inhibitors

Indexed keywords

CLADRIBINE; DASATINIB; IMATINIB; ISOLEUCINE; LYSINE; MIDOSTAURIN; TRYPTASE; 4'-N-BENZOYLSTAUROSPORINE; BENZAMIDE DERIVATIVE; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STAUROSPORINE; STEM CELL FACTOR RECEPTOR; THIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GERMLINE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MUTATIONAL ANALYSIS; ONCOGENE C KIT; PANCYTOPENIA; RASH; SKIN BIOPSY; SPLENECTOMY; SPLENOMEGALY; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME; DRUG EFFECT; FAMILIAL MASTOCYTOSIS; GENETICS; K509I KIT MUTATION; NUCLEOTIDE SEQUENCE; TYROSINE KINASE INHIBITORS; WESTERN BLOTTING; YOUNG ADULT;

DASATINIB; FAMILIAL MASTOCYTOSIS; IMATINIB; K509I KIT MUTATION; PKC412; TYROSINE KINASE INHIBITORS;

ADULT; APOPTOSIS; BASE SEQUENCE; BENZAMIDES; BLOTTING, WESTERN; FEMALE; GERM-LINE MUTATION; HUMANS; MASTOCYTOSIS, SYSTEMIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; STAUROSPORINE; THIAZOLES; YOUNG ADULT;

EID: 84908024600     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.07.010     Document Type: Article

References (38)

1. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Sanchez M.L., Nunez R., Prados A., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
2. Sanchez-Munoz L., Alvarez-Twose I., Garcia-Montero A.C., Teodosio C., Jara-Acevedo M., Pedreira C.E., et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2001, 24:1157-1168.
3. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625.
4. Escribano L., Akin C., Castells M., Orfao A., Metcalfe D.D. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002, 81:677-690.
5. Valent P., Akin C., Sperr W.R., Escribano L., Arock M., Horny H.P., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003, 27:635-641.
6. Horny H., Metcalfe D., Bennet J., Bain B., Akin C., Escribano L., et al. Mastocytosis. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 54-63. IARC Press, Lyon. S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman (Eds.).
7. Georgin-Lavialle S., Lhermitte L., Dubreuil P., Chandesris M.O., Hermine O., Damaj G. Mast cell leukemia. Blood 2013, 121:1285-1295.
8. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol 2013, 88:612-624.
9. Fowler J.F., Parsley W.M., Cotter P.G. Familial urticaria pigmentosa. Arch Dermatol 1986, 122:80-81.
10. Clark D.P., Buescher L., Havey A. Familial urticaria pigmentosa. Arch Intern Med 1990, 150:1742-1744.
11. Oku T., Hashizume H., Yokote R., Sano T., Yamada M. The familial occurrence of bullous mastocytosis (diffuse cutaneous mastocytosis). Arch Dermatol 1990, 126:1478-1484.
12. Anstey A., Lowe D.G., Kirby J.D., Horton M.A. Familial mastocytosis: a clinical, immunophenotypic, light and electron microscopic study. Br J Dermatol 1991, 125:583-587.
13. Chang A., Tung R.C., Schlesinger T., Bergfeld W.F., Dijkstra J., Kahn T.A. Familial cutaneous mastocytosis. Pediatr Dermatol 2001, 18:271-276.
14. Hartmann K., Wardelmann E., Ma Y., Merkelbach-Bruse S., Preussner L.M., Woolery C., et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005, 129:1042-1046.
15. Wasag B., Niedoszytko M., Piskorz A., Lange M., Renke J., Jassem E., et al. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. Exp Hematol 2011, 39. 859-65 e2.
16. Kunstlinger H., Huss S., Merkelbach-Bruse S., Binot E., Kleine M.A., Loeser H., et al. Gastrointestinal Stromal tumors with KIT exon 9 mutations: update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 2013, 37:1648-1659.
17. Zanotti R., Simioni L., Garcia-Montero A.C., Perbellini O., Bonadonna P., Caruso B., et al. Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. J Allergy Clin Immunol 2013, 131:605-607.
18. Ning Z.Q., Li J., Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001, 97:3559-3567.
19. Rottapel R., Reedijk M., Williams D.E., Lyman S.D., Anderson D.M., Pawson T., et al. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol Cell Biol 1991, 11:3043-3051.
20. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999, 31:1053-1074.
21. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995, 92:10560-10564.
22. Akin C., Brockow K., D'Ambrosio C., Kirshenbaum A.S., Ma Y., Longley B.J., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686-692.
23. Zermati Y., De Sepulveda P., Feger F., Letard S., Kersual J., Casteran N., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003, 22:660-664.
24. Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011, 35:1143-1152.
25. Traina F., Visconte V., Jankowska A.M., Makishima H., O'Keefe C.L., Elson P., et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE 2012, 7:e43090.
26. Schwaab J., Schnittger S., Sotlar K., Walz C., Fabarius A., Pfirrmann M., et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013, 122:2460-2466.
27. Traina F., Carvalheira J.B., Saad M.J., Costa F.F., Saad S.T. BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Lett 2003, 535:17-22.
28. Akin C., Escribano L., Nuñez R., Garcia-Montero A., Angulo M., Orfao A., et al. Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations. J Allergy Clin Immunol 2004, 113(Suppl.):S327.
29. Valent P., Sotlar K., Sperr W.R., Escribano L., Yavuz S., Reiter A., et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014, [Epub ahead of print]. 10.1093/annonc/mdu047.
30. Zhang L.Y., Smith M.L., Schultheis B., Fitzgibbon J., Lister T.A., Melo J.V., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006, 30:373-378.
31. Chan E.C., Bai Y., Kirshenbaum A.S., Fischer E.R., Simakova O., Bandara G., et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol 2014, 134. 178-87 e1.
32. Pagano L., Valentini C.G., Caira M., Rondoni M., Van Lint M.T., Candoni A., et al. Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol 2008, 88:483-488.
33. Schittenhelm M.M., Shiraga S., Schroeder A., Corbin A.S., Griffith D., Lee F.Y., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
34. Verstovsek S., Tefferi A., Cortes J., O'Brien S., Garcia-Manero G., Pardanani A., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14:3906-3915.
35. Gleixner K.V., Mayerhofer M., Aichberger K.J., Derdak S., Sonneck K., Bohm A., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006, 107:752-759.
36. Feng L.X., Ravindranath N., Dym M. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 2000, 275:25572-25576.
37. Growney J.D., Clark J.J., Adelsperger J., Stone R., Fabbro D., Griffin J.D., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106:721-724.
38. Roberts K.G., Odell A.F., Byrnes E.M., Baleato R.M., Griffith R., Lyons A.B., et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007, 6:1159-1166.